Endpoints' Drew Armstrong and FTC deputy director Rahul Rao at the Financial Times' US Pharma and Biotech Summit (Sarah Merians Photography for Endpoints News)
Q&A: FTC’s top healthcare enforcer on pharma M&A, company growth and PBMs
The Federal Trade Commission has loomed large over M&A in the biopharma industry in the last two years. The antitrust regulator attempted to block Amgen …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
